A
Agilent TechnologiesNYSEHealth CareDiagnostics & ResearchSnapshot 2026-05-08
As of May 8, 2026, stock A has a composite score of 24.3 and a signal label of "mild favorable." The guidance credibility score increased to 91.2, rising by 12.4 points, which is a significant driver of the current scoring. However, the overall assessment remains provisional, with several unfavorable scenarios impacting the composite delta estimates.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.00
- Bonus0.00
Why this rank
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $1.50 → $1.50 (+0.1% / 30d). 2 raised, 0 cut, 13 covering analysts.
0 upgrades, 0 downgrades / 30d, 3 maintained. 78% of analysts rate Buy.
1 PT revisions / 30d. Avg target 19.1% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
17 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Revenue growth for fiscal year 2026growthmixed65% progress
2/25: “Fiscal year 2026 revenue is expected in the range of $7.3 billion to $7.5 billion.”
Why this status
Stated in 3 of last 3 quarters. Revenue grew from $6.95B in 2025 to $7.3B-$7.5B guidance for 2026. The trajectory aligns with management's stated growth target, indicating progress towards achieving fiscal year 2026 revenue goals.
- 2.Non-GAAP EPS guidance for fiscal year 2026growthmixed65% progress
2/25: “Non-GAAP EPS is expected in the range of $5.90 to $6.04.”
Why this status
Stated in 3 of last 3 quarters. EPS guidance increased from $5.86-$6.00 to $5.90-$6.04. The consistent upward revision in EPS guidance suggests management's confidence in achieving the fiscal year 2026 targets.
- 3.Revenue guidance for Q2 2026growthmixed65% progress
2/25: “Fiscal second-quarter 2026 revenue guidance is expected in the range of $1.79 billion to $1.82 billion.”
Why this status
Stated in 2 of last 2 quarters. Q2 2026 revenue guidance set at $1.79B-$1.82B. The guidance reflects management's expectation of continued growth, aligning with the company's strategic focus on revenue expansion.
Guidance track record
Last 8 quarters of EPS guidance with actuals.
Per-quarter detail
| Period | Guidance | Actual | Result |
|---|---|---|---|
| 2024-04-30 | $1.17 – $1.20 | $1.22 | beat |
| 2024-07-31 | $1.25 – $1.28 | $1.32 | beat |
| 2024-10-31 | $1.38 – $1.42 | $1.46 | beat |
| 2025-01-31 | $1.25 – $1.28 | $1.31 | beat |
| 2025-04-30 | $1.25 – $1.28 | $1.31 | beat |
| 2025-07-31 | $1.35 – $1.37 | $1.37 | inside |
| 2025-10-31 | $1.57 – $1.60 | $1.59 | inside |
| 2026-01-31 | $1.35 – $1.38 | $1.36 | inside |
Beat / inside / miss is computed from the guided range when issued; for point-estimate quarters a ±5% tolerance band around the mid is used. surprise_pct_vs_mid is unstable when guided EPS is near zero, so it is not surfaced as a headline.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 34%; 252d 30%.
Drawdown — Max 1y −30%. Bad day move −3%.
Beta to sector ETF (XLV) — 1.20 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 51/100, drawdown 41/100, beta 80/100, earnings vol —.
Calm + bullish setup — clean pre-earnings positioning pattern.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- score change · guidance_credibility_scoreseverity 31
Guidance credibility rose by 12.4 points (from 78.8 to 91.2).
As of 2026-05-08, the guidance credibility score for A rose by 12.4 points, increasing from 78.8 to 91.2. The overall signal transitioned to "mild_favorable." The forward view indicates unfavorable scenarios, including a potential guidance cut and labor state reversal, alongside a favorable scenario if the health care sector trend improves. This information is provisional.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 88% of the last 8 guided quarters · 2.8% avg surprise
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Revenue growth for fiscal year 2026
GrowthNew since 2026-05-04Focus on achieving revenue growth between 5.5% to 7.5% for fiscal year 2026.
On track →MixedStated in 3 of last 3 quarters. Revenue grew from $6.95B in 2025 to $7.3B-$7.5B guidance for 2026. The trajectory aligns with management's stated growth target, indicating progress towards achieving fiscal year 2026 revenue goals.
Revenue grew from $6.95B in 2025 to $7.3B-$7.5B guidance for 202665%CEO/CFO:“Fiscal year 2026 revenue is expected in the range of $7.3 billion to $7.5 billion.”Press releaseSource dated 2026-02-25Stated 3 of last 8 quartersFirst seen 2026-05-04Show history (3)
- 2026-Q1Press release
“Fiscal year 2026 revenue is expected in the range of $7.3 billion to $7.5 billion.”
- 2025-Q4Press release
“Fiscal year 2026 revenue is expected in the range of $7.3 billion to $7.4 billion.”
- 2025-Q3Press release
“Full-year revenue outlook revised at a range of $6.91 billion to $6.93 billion.”
- #2
Non-GAAP EPS guidance for fiscal year 2026
GrowthNew since 2026-05-04Maintain non-GAAP EPS guidance in the range of $5.90 to $6.04 for fiscal year 2026.
On track →MixedStated in 3 of last 3 quarters. EPS guidance increased from $5.86-$6.00 to $5.90-$6.04. The consistent upward revision in EPS guidance suggests management's confidence in achieving the fiscal year 2026 targets.
EPS guidance increased from $5.86-$6.00 to $5.90-$6.0465%CEO/CFO:“Non-GAAP EPS is expected in the range of $5.90 to $6.04.”Press releaseSource dated 2026-02-25Stated 3 of last 8 quartersFirst seen 2026-05-04Show history (3)
- 2026-Q1Press release
“Non-GAAP EPS is expected in the range of $5.90 to $6.04.”
- 2025-Q4Press release
“Non-GAAP EPS is expected in the range of $5.86 to $6.00.”
- 2025-Q3Press release
“Non-GAAP EPS is expected in the range of $5.56 to $5.59.”
- #3
Revenue guidance for Q2 2026
GrowthNew since 2026-05-04Achieve revenue growth of approximately 7% to 9% for Q2 2026.
On track →MixedStated in 2 of last 2 quarters. Q2 2026 revenue guidance set at $1.79B-$1.82B. The guidance reflects management's expectation of continued growth, aligning with the company's strategic focus on revenue expansion.
65%CEO/CFO:“Fiscal second-quarter 2026 revenue guidance is expected in the range of $1.79 billion to $1.82 billion.”Press releaseSource dated 2026-02-25Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Press release
“Fiscal second-quarter 2026 revenue guidance is expected in the range of $1.79 billion to $1.82 billion.”
- 2025-Q4Press release
“Fiscal first-quarter 2026 revenue guidance is expected in the range of $1.79 billion to $1.82 billion.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks more expensive than peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
61 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
A Agilent Technologies | +24 | fair | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is cut (currently RAISED as of 2026-02-25)-16 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
- If rates state reverses from -0.37 (negative) to +0.37 (positive)-2.9 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-045d agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) As previously disclosed, on March 31, 2026, Bret DiMarco, Senior Vice President, Chief Legal Officer and Secretary of Agilent Technologies, Inc. (the “Company”), entered into a transition and general release agreement with the Company (the “Transition Agreement”) pursuant to which Mr. DiMarco will resign from such roles upon the earlier to occu…
executive changeneutralscore 50 - 2026-04-041mo agoItem 5.01
of Form 8-K. The sole purpose of this amendment is to correct the EDGAR submission header for the Original 8-K as disclosure under
mna activityneutralscore 36 - 2026-04-041mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On March 31, 2026, Bret DiMarco, Senior Vice President, Chief Legal Officer and Secretary of Agilent Technologies, Inc. (the “Company”), entered into a transition and general release agreement with the Company (the “Transition Agreement”) pursuant to which Mr. DiMarco will resign from such roles upon the earlier to occur of the start date of a…
executive changeneutralscore 25 - 2026-04-031mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On March 31, 2026, Bret DiMarco, Senior Vice President, Chief Legal Officer and Secretary of Agilent Technologies, Inc. (the “Company”), entered into a transition and general release agreement with the Company (the “Transition Agreement”) pursuant to which Mr. DiMarco will resign from such roles upon the earlier to occur of the start date of a…
executive changeneutralscore 25 - 2026-03-062mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On March 5, 2026, Rodney Gonsalves, informed Agilent Technologies, Inc. ("Agilent") that he would retire from his position as Agilent’s Vice President, Corporate Controller and Principal Accounting Officer in January 2027, the exact date to be determined at a later time. Mr. Gonsalves' departure is not related to any disagreement with Agilent o…
executive changeneutralscore 13
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.